The introduction of targeted cancer drugs has revolutionized cancer treatment, especially in patients with colorectal cancer (CRC) or non–small-cell lung cancer (NSCLC). These drugs have been accompanied by genomic assays that test for certain mutations, such as ALK
, or EGFR
, which often help guide cancer treatment decisions by identifying patients who would benefit most from certain therapies over others. However, there are few data regarding the real-world use of genomic tests among oncologists for these cancers.
[ Read More ]